Drooling in Children with Special Health Care Needs
Reflux, nausea, teething, malocclusion, enlarged tongue or persistent tongue thrust, painful oropharyngeal or esophageal lesions such as herpes, and use or exposure to certain drugs (e.g. antipsychotics especially clozapine, and some antibiotics, tranquilizers, and medications used to treat Alzheimers) or chemicals (such as mercury) can also contribute to drooling. [Meningaud: 2006] Children with neurodevelopmental or neuromuscular disorders, genetic conditions (e.g., Rett syndrome), traumatic brain injury, and dysautonomia are at increased risk of sialorrhea.
Approximately 1/3 of children with cerebral palsy or other neurological conditions have sialorrhea, although not all of these children have problematic drooling. [Rapoport: 2010] The following aims to help clinicians and families discuss treatment options when a child has persistent, problematic drooling.
Assessment
Parents may not be aware of interventions that can reduce drooling, so the clinician should ask the child and family how much the persistent drooling impacts them and if they would like to explore interventions. In addition to social stigma, drooling can contribute to odor, rash, chapped lips, mouth infections, aspiration, dehydration, stained clothes, frequent laundry, and ruined computers or other hardware. [Walshe: 2012] [Rapoport: 2010] Encourage parents to ask the child's teacher about the amount of drooling observed at school and its social impact on the child.
Assessment scales can be used before and after treatment to monitor its
effectiveness. Examples include the Drooling Quotient, Drooling Severity and
Frequency Scale [Rashnoo: 2015], and The Drooling Impact Scale ( 100 KB) . [Reid: 2010]
The Teacher's Drooling Scale , below, is a brief assessment tool to help track drooling over time and in response to treatment; the Modified Teacher's Drooling Scale has 4 additional questions to more finely gauge drooling severity.
Teacher Drooling Scale [Robert: 2000]
- No drooling
- Infrequent drooling, small amount
- Occasional drooling, on and off all day
- Frequent drooling, but not profusely
- Constant drooling, always wet
Treatment
Response to treatment is variable; multiple trials may be valuable in finding the best approach. The clinician can work with the family and pediatric specialists to discuss options and determine when intervention trials are warranted.
Pearls & Alerts
As an off-label use, atropine drops are sometimes used sublingually to treat drooling:
- Premoisten cotton-tipped applicator -- hold tip upright and apply 2-4 drops normal saline
- Apply 2-6 drops of atropine 1% ophthalmic solution to the pre-moistened applicator tip
- Swab/twist applicator inside one cheek for 10 seconds.
- Repeat using new applicator, saline, and atropine drops for the other cheek.
- May repeat the process every 6-8 hours as needed.
Anticholinergic medications are occasionally requested by parents for short-term benefit during an important occasion (e.g., a family wedding). Although these medications might decrease drooling in the acute setting, they may also cause drowsiness. Families should try the medication prior to the event to assess response and side effects.
During respiratory illnesses affecting the child’s airway, the clinician may consider adjusting the child’s antisialorrheic medication dose up or down to either decrease secretions or reduce the thickness of the secretions. Increase fluid intake accordingly if the child has increased losses from excessive secretions.
Therapies
Medications
- Atropine
- 2-6 drops per cheek of the 1% solution every 6-8 hours (see Pearls & Alerts, above)
- Alternative dosing: 1-2 drops of 0.5% ophthalmic solution every 4-6 hours may be used sublingually, providing local treatment and resulting in fewer systemic side effects or medication interactions. [Rapoport: 2010] Another study noted that several parents found it difficult to administer. [Norderyd: 2017]
- Atropine gel is also undergoing phase 2 clinical study.
- There is still a potential risk of systemic anticholinergic side effects; however, sublingual atropine has lower potential for side effects and medication interactions compared to glycopyrrolate.
- Glycopyrrolate
- The solution formulation was approved by the FDA in 2010 for children ages 3-16 years with neurologic disorders and severe sialorrhea. [Eiland: 2012]
- Patients with Down syndrome and children with spastic paralysis or brain damage may be hypersensitive to antimuscarinic effects. See Glycopyrrolate (Drugs.com).
- Dosing recommendations for oral use vary among studies. One controlled trial in the United Kingdom used gradual upward titration from 0.04-0.1 mg/kg/dose, up to 3-4 times per day orally or via feeding tube; max 2 mg. [Parr: 2018] [Rapoport: 2010]
- Scopolamine (hyoscine) patch
- In the United Kingdom, this medication is used more frequently than glycopyrrolate for problematic drooling; however, it has more side effects than glycopyrrolate. [Parr: 2018] It is well known as a treatment to prevent motion sickness.
- Patients with Down syndrome and children with spastic paralysis or brain damage may be hypersensitive to antimuscarinic effects. See Glycopyrrolate (Drugs.com).
- A pediatric drug trial evaluated dosing ranges of ¼-1 full transdermal patch every 3 days, but the patches are not designed to be cut. [Parr: 2018]
- Another trial used 1 patch every 3 days in children >12 years. [Rapoport: 2010]
- A safe and effective pediatric dose has not been established in the U.S. See Scolopamine Patch (Drugs.com).
- Benzhexol (trihexyphenidyl)
- Drug information recommends that patients should undergo a gonioscope evaluation of intraocular pressures prior to use and receive close monitoring of intraocular pressures periodical during use. Do not use the drug in children <3 years of age. See Benzhexol (Drugs.com) and Trihexyphenidyl (Encyclopedia of Mental Disorders).
- In a study of off-label use of this medication for treatment of dystonia or sialorrhea in children with cerebral palsy, it was generally well tolerated and effective. [Carranza-del: 2011]
- Dosing in the study increased gradually from a mean of 0.095 mg/kg/day to around 0.55 mg/kg/day divided 2 or 3 times per day with higher doses associated with increased side effects. [Carranza-del: 2011]
Surgery
Complementary and Alternative Medicine
Subspecialist Collaboration
Pediatric Physical Medicine & Rehabilitation (Pediatric Physical Medicine & Rehabilitation
(see RI providers
[6]))
Provide treatments for sialorrhea including medications or botulinum injections. They also help determine appropriate therapies
and specialist referrals, and adjust medications that may contribute to drooling.
Pediatric Otolaryngologists (Pediatric Otolaryngology (ENT)
(see RI providers
[7]))
Provide treatments for sialorrhea including medications, botulinum injections, or surgery.
Pediatric Ophthalmologists (Pediatric Ophthalmology
(see RI providers
[8]))
Perform gonioscope evaluations prior to and during use of certain medications like Benzhexol.
Speech Pathologists (Speech - Language Pathologists
(see RI providers
[32]))
Work with patients to improve control of oromotor and feeding skills.
Occupational Therapist
(Occupational Therapy
(see RI providers
[20]))
Work with patients to improve feeding skills.
Resources
Information & Support
For Parents and Patients
Seven Tips to Stop Your Child with Special Needs from Drooling (Friendship Circle)Tools
Drooling Impact Scale ( 100 KB)
A 5-minute, 10-question screen to help measure the impact drooling is having on the child and family.
Modified Teacher's Drooling Scale (MTDS)
A free, 9-point scoring system measured by parents/caregivers. Scores range from 1 to 9, with a higher score indicating more
severe drooling.
Services for Patients & Families in Rhode Island (RI)
Service Categories | # of providers* in: | RI | NW | Other states (3) (show) | | NM | NV | UT |
---|---|---|---|---|---|---|---|---|
General Dentistry | 35 | 1 | 12 | 18 | 98 | |||
Occupational Therapy | 20 | 1 | 17 | 27 | 36 | |||
Orthodontics | 3 | 4 | 18 | |||||
Pediatric Dentistry | 41 | 2 | 6 | 32 | 50 | |||
Pediatric Ophthalmology | 8 | 1 | 6 | 6 | 4 | |||
Pediatric Otolaryngology (ENT) | 7 | 1 | 11 | 5 | 9 | |||
Pediatric Physical Medicine & Rehabilitation | 6 | 3 | 3 | 3 | 11 | |||
Speech - Language Pathologists | 32 | 4 | 23 | 14 | 65 |
For services not listed above, browse our Services categories or search our database.
* number of provider listings may vary by how states categorize services, whether providers are listed by organization or individual, how services are organized in the state, and other factors; Nationwide (NW) providers are generally limited to web-based services, provider locator services, and organizations that serve children from across the nation.
Helpful Articles
Walshe M, Smith M, Pennington L.
Interventions for drooling in children with cerebral palsy.
Cochrane Database Syst Rev.
2012;11:CD008624.
PubMed abstract
Cochrane review of studies of safety and effectiveness of interventions for problematic sialorrhea in children.
Rapoport A.
Sublingual atropine drops for the treatment of pediatric sialorrhea.
J Pain Symptom Manage.
2010;40(5):783-8.
PubMed abstract
Case study of pediatric application of sublingual atropine for drooling. Also contains dosing guidance for several anticholinergics
used to treat sialorrhea.
Authors & Reviewers
Author: | Jennifer Goldman, MD, MRP, FAAP |
2016: update: Meghan S Candee, MD, MScA; Nicholas Johnson, MD, MS-CIA |
2013: first version: Lynne M. Kerr, MD, PhDA; Lisa Samson-Fang, MDA |
Page Bibliography
Carranza-del Rio J, Clegg NJ, Moore A, Delgado MR.
Use of trihexyphenidyl in children with cerebral palsy.
Pediatr Neurol.
2011;44(3):202-6.
PubMed abstract
Eiland LS.
Glycopyrrolate for chronic drooling in children.
Clin Ther.
2012;34(4):735-42.
PubMed abstract
Garnock-Jones KP.
Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions.
Paediatr Drugs.
2012;14(4):263-9.
PubMed abstract
Inga CJ, Reddy AK, Richardson SA, Sanders B.
Appliance for chronic drooling in cerebral palsy patients.
Pediatr Dent.
2001;23(3):241-2.
PubMed abstract
Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC.
Drooling of saliva: a review of the etiology and management options.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2006;101(1):48-57.
PubMed abstract
Mikami DLY, Furia CLB, Welker AF.
Addition of Kinesio Taping of the orbicularis oris muscles to speech therapy rapidly improves drooling in children with neurological
disorders.
Dev Neurorehabil.
2017:1-6.
PubMed abstract
Small study to evaluate the effects of Kinesio Taping applied to the orbicularis oris muscles as an adjunct to standard speech
therapy for drooling.
Moulding MB, Koroluk LD.
An intraoral prosthesis to control drooling in a patient with amyotrophic lateral sclerosis.
Spec Care Dentist.
1991;11(5):200-2.
PubMed abstract
Norderyd J, Graf J, Marcusson A, Nilsson K, Sjöstrand E, Steinwall G, Ärleskog E, Bågesund M.
Sublingual administration of atropine eyedrops in children with excessive drooling - a pilot study.
Int J Paediatr Dent.
2017;27(1):22-29.
PubMed abstract / Full Text
Parr JR, Todhunter E, Pennington L, Stocken D, Cadwgan J, O'Hare AE, Tuffrey C, Williams J, Cole M, Colver AF.
Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium
liquid on drooling in children with neurodisability.
Arch Dis Child.
2018;103(4):371-376.
PubMed abstract / Full Text
Rapoport A.
Sublingual atropine drops for the treatment of pediatric sialorrhea.
J Pain Symptom Manage.
2010;40(5):783-8.
PubMed abstract
Case study of pediatric application of sublingual atropine for drooling. Also contains dosing guidance for several anticholinergics
used to treat sialorrhea.
Rashnoo P, Daniel SJ.
Drooling quantification: Correlation of different techniques.
Int J Pediatr Otorhinolaryngol.
2015;79(8):1201-5.
PubMed abstract
Compares the Drooling Quotient (DQ) score with the questionnaire-based Drooling Severity and Frequency Scale (DSFS) to the
number of bibs changed per day; recommends the DSFS as a quick and comparable assessment tool.
Reid SM, Johnson HM, Reddihough DS.
The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities.
Dev Med Child Neurol.
2010;52(2):e23-8.
PubMed abstract
Describes the development of the Drooling Impact Scale for use in measuring severity of drooling.
Robert E. Nickel, M.D. & Larry W. Desch, M.D.
The Physician's Guide to Caring for Children with Disabilities and Chronic Conditions.
Baltimore, MD: Paul H. Brookes Publishing Co.;
2000.
1-55766-446-3
van der Burg JJW, Sohier J, Jongerius PH.
Generalization and maintenance of a self-management program for drooling in children with neurodevelopmental disabilities:
A second case series.
Dev Neurorehabil.
2018;21(1):13-22.
PubMed abstract
Small study of a program in children with oral-motor problems and normal intelligence or mild intellectual disabilities that
appeared to be helpful in self-management of drooling.
Walshe M, Smith M, Pennington L.
Interventions for drooling in children with cerebral palsy.
Cochrane Database Syst Rev.
2012;11:CD008624.
PubMed abstract
Cochrane review of studies of safety and effectiveness of interventions for problematic sialorrhea in children.
Zeller RS, Davidson J, Lee HM, Cavanaugh PF.
Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral
palsy and other neurologic conditions.
Ther Clin Risk Manag.
2012;8:25-32.
PubMed abstract / Full Text
Discusses the adverse effects as well as the benefits from a study comparing use of glycopyrrolate to placebo for treatment
of severe childhood drooling.
Zeller RS, Lee HM, Cavanaugh PF, Davidson J.
Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic
severe drooling in children with cerebral palsy or other neurologic conditions.
Ther Clin Risk Manag.
2012;8:15-23.
PubMed abstract / Full Text
Randomized controlled trial showing benefits of oral glycopyrrolate solution to control severe drooling in children compared
to placebo.